Skip to main content
. 2021 Aug 4;75(11):776–781. doi: 10.1136/jclinpath-2021-207441

Table 2.

Immunohistochemical results of five patients with UTROSCT

Case 1 Case 2 Case 3 Case 4 Case 5
CK 1+ 1+ 1+ 2+ 2+
WT-1 3+ 2+
CD99 2+ 2+ 2+ 2+
CR 2+ 2+ 2+ 2+
α-Inhibin 1+
SF-1 2+ 2+ 2+
EMA
Desmin 2+ 2+ 1+
SMA 2+ 1+ 1+ 3+
h-Caldesmon 2+ 2+ 2+ 2+ 1+
BCL-2 3+ 3+ 3+ 3+ 3+
ER 1+ 1+ 2+ 3+ 2+
PR 3+ 3+ 3+ 3+ 2+
CD10 1+ 1+ 1+ 1+

‘–’ indicates negativity; ‘1+’ denotes weak or focal positivity, with a number of positive cells <25%; ‘2+’ indicates moderate positivity, with a number of positive cells of 25%–75%; ‘3+’ denotes diffuse strong positivity, with a number of positive cells >75%.

BCL-2, B cell lypmphoma-2; CD10, cluster of differentiation 10; CD99, cluster of differentiation 99; CK, cytokeratin; EMA, epithelial membrane antigen; ER, oestrogen receptor; PR, progesterone receptor; SF-1, steroidogenic factor-1; SMA, smooth muscle actin; UTROSCT, tumours resembling ovarian sex cord tumour; WT-1, Wilms' tumour 1.